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A B S T R A C T
Background: In the past decade, a large inﬂux of migrants presented in Europe. Their country of origin was
mainly either Syria or Eritrea. Public health institutions in host countries in Europe are challenged to screen and
care for migrant populations with regard to infectious diseases.
Methods: We performed a systematic literature review (according to PRISMA guidelines) to deﬁne the infectious
disease proﬁle of migrants originating in Syria and Eritrea.
Results: The search resulted in 825 papers of possible relevance for infectious diseases in migrants from Syria, of
which, after screening, we included 35 in the systematic review. A further 265 papers of possible relevance for
infectious diseases in Eritrean migrants were screened, of which we included 27 in the systematic review.
In migrants from Syria, leishmaniasis was the most frequently reported infectious disease. In addition, co-
lonisation with drug resistant, Gram-negativ bacteria was reported. In the Eritrean migrants the infectious
disease most described in the selected papers was louse-borne relapsing fever. Other frequently reported in-
fectious diseases were scabies and Plasmodium vivax malaria.
Conclusion: Our systematic analysis deﬁnes the proﬁles of infectious diseases for migrants from Syria and Eritrea
and serves as an evidence base for public health screening and care of presenting migrants.
1. Introduction
Since 2008, the number of refugees migrating to Europe has steadily
increased. While the total number of ﬁrst time asylum applicants in the
European Union was around 225′000 in 2008, it rose to 1.3 million in
2015 and stayed at this level in 2016 [1]. At the end of 2016, 5.2
million refugees were hosted in European countries, with 2.9 million
refugees in Turkey alone [2].
The civil war in Syria, which started in 2011 and still ongoing, with a
death toll of 250′000 by 2015 [3], has resulted in a large, forcibly displaced,
Syrian population, with a count of 12million displaced persons at the end of
2016; this includes 5.5 million refugees, 6.3 million internally displaced
persons (IDPs) and nearly 185,000 asylum-seekers [2].
Most Syrian migrants leave their country of origin via Turkey. While a
signiﬁcant number of the refugees stay in this country, others continue
overland to Western Europe via Greece and the « Balkan route » [4] (Fig. 1).
87% of the Syrian refugees were accommodated in neighbouring
countries and Turkey hosted the largest population of Syrian refugees
(over 2.8 million). In Turkey, Syrian refugees are granted temporary
protection&#8232;on a group basis under the Temporary Protection
regime, whereas other nationalities undergo an individual refugee
status determination procedure.
Other countries in the region with signiﬁcant numbers of Syrian
refugees include Lebanon and Jordan. In Europe, the number of Syrian
refugees is highest in Germany and Sweden. In 2016, more than 25% of
the asylum seekers in the European Union were of Syrian origin [5].
A second major wave of refugees in Europe originates from Eritrea
located on the Horn of Africa. Eritrea remained the ninth-largest
country of origin of refugees at the end of 2016 with more than 450′000
refugees [2]. In Switzerland, Eritrean migrants constitute an important
group of migrants. In 2015, 25% of all applications of asylum in Europe
from Eritreans were in Switzerland [6]. This is why we chose Eritreans
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as a contrasting group to Syrians as they are likely to have a diﬀerent
origin, migration route and proﬁle of infectious disease.
Since the Eritrean-Ethiopian War (1998–2000) all Eritreans are
forced to serve in the „National service“ (army or civil service) for an
indeﬁnite period and without hope of leaving [6]. This forced con-
scription presents the major reason for Eritreans to migrate.
Eritrean migrants are usually between 15 and 30 years old. The
most frequent migration route chosen by migrants from Eritrea is
through Ethiopia and/or Sudan before embarking from Libya to Europe
on the “Central Mediterranean” route [7,8] (Fig. 1).
Most Eritrean refugees were hosted by Ethiopia and Sudan, but
many also sought asylum further away in more northerly countries. In
Europe, Sweden, Germany, Norway, the Netherlands and Switzerland
represent the most important destinations for this group [6].
Due to these developments it has recently become even more im-
portant to analyze the potential infectious disease health risks, both for
the migrants and for the host countries that might accompany this
signiﬁcant mobilization of people. Therefore the main goal of this paper
is to collate data on the infectious disease proﬁles of Syrian and Eritrean
refugees to form an evidence basis for screening programs and care
strategies to address healthcare issues in migrant populations.
A secondary goal is to evaluate the extent of infectious disease risk,
if any, posed to destination countries as this will have an impact on
socio-political approaches to health needs in the mobile and host
communities.
2. Methods
This systematic review was conducted according to the Preferred
Reporting Items for Systematic Reviews and meta-Analysis (PRISMA)
statement [9]. A systematic review of the literature regarding infectious
diseases of migrants from Syria and Eritrea was performed using the
databases PubMed, Embase, Scopus and CINAHL. The period of the
study for data collection was January 2014–March 2017.
The literature search strategy included the words infect*, together
with migra* or refugee* and Syria* or Eritrea* or a combination of the
afore-mentioned terms. The asterisk was used for abridged terminology.
The main author (EI) scanned the titles of all identiﬁed papers.
All citations obtained from the literature searches were scanned by
one author (EI) who removed duplicates. Two authors (EI and PS) then
Fig. 1. Major migrant routes for Syrian and Eritrean from their country of
origin to their country of destination.
Source: basic map: www.outline-world-map.com; Egon Isenring.
Fig. 2. Prisma ﬂow chart for the selection of papers on infectious disease in Syrian migrants.
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scrutinised the citations in detail and made an independent selection
among the full-text articles assessed for egibility, discussed their
choices and consequently agreed upon a ﬁnal selection. Full-text ana-
lysis was performed for all the included articles. Finally, 35 papers of
infection diseases of migrants and refugees from Syria and 27 papers
concerning infections diseases of migrants and refugees from Eritrea
were included in this systematic review (Prisma ﬂow charts for both
searches are shown in Figs. 2 and 3). Full details of our search strategy
are provided in Appendix 1.
In papers where migrant groups were evaluated without a clear
breakdown of infection according to the origin of the migrants, we
contacted the corresponding authors of the respective papers to acer-
tain the exact details.
A dot-based, infection proﬁle graphic was also created quantifying
the numbers of papers regarding key infections divided by migrant
origin in Syrian or Eritrean showing the proﬁles of infection according
to the papers identiﬁed in the graph.
With regard to deﬁnitions used, we based these on the International
Organization for Migration (IOM) deﬁnitions as follows: “Asylum-
seeker” as a person who seeks safety from persecution or serious harm in a
country other than his or her own and awaits a decision on the application
for refugee status under relevant international and national instruments. In
case of a negative decision, the person must leave the country and may be
expelled, as may any non-national in an irregular or unlawful situation,
unless permission to stay is provided on humanitarian or other related
grounds.
“Refugee” was deﬁned as a person who, “owing to a well-founded
fear of persecution for reasons of race, religion, nationality, member-
ship of a particular social group or political opinions, is outside the country
of his nationality and is unable or, owing to such fear, is unwilling to avail
himself of the protection of that country. (Art. 1(A) (2), Convention relating
to the Status of Refugees, Art. 1A(2), 1951 as modiﬁed by the 1967
Protocol). In addition to the refugee deﬁnition in the 1951 Refugee
Convention, Art. 1(2), 1969 Organization of African Unity (OAU)
Convention deﬁnes a refugee as any person compelled to leave his or her
country "owing to external aggression, occupation, foreign domination or
events seriously disturbing public order in either part or the whole of his
country or origin or nationality." Similarly, the 1984 Cartagena Declaration
states that refugees also include persons who ﬂee their country "because their
lives, security or freedom have been threatened by generalised violence,
foreign aggression, internal conﬂicts, massive violations of human rights or
other circumstances which have seriously disturbed public order." [10].
3. Results
For the Syrian analysis, the initial search yielded 825 records and
after exclusions and duplicates, we included 35 in the ﬁnal qualitative
analysis (Fig. 2).
Most of the identiﬁed articles for the migrants and refugees from
Syria addressed leishmaniasis (n= 10), followed by articles containing
information about tuberculosis (n= 6), gram-negative bacteria (6) and
sabin-like polio (n= 5). Other infectious diseases which were identiﬁed
in less than 5 articles (Table 1).
For the Eritrean analysis, the initial search yielded 265 records and
after exclusions and duplicates, we included 27 in the ﬁnal qualitative
analysis (Fig. 3).
Most of the identiﬁed articles for the migrants and refugees from
Eritrea addressed Louse bourne relapsing fever (n=8), followed by
articles containing information about tuberculosis (n= 6), scabies
(n= 5), malaria (n= 4) and schistosoma (n= 4) (Table 2). There were
some other infectious diseases which were identiﬁed by less than 4
articles (see Fig. 4).
Fig. 3. Prisma ﬂow chart for the selection of papers on infectious disease in Eritrean migrants.
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3.1. Infectious disease papers addressing Syrian migrants (results)
3.1.1. Leishmaniasis
The cases of leishmaniasis identiﬁed in the studies of this systematic
review were equally distributed between the sexes. The majority of
cases concern individuals aged less than 20 years. Most of the cases
were cutaneous leishmaniasis (CL), primarily with lesions in the head
and neck area and most of all on the face [11–13].
Leishmania tropica was the most frequently reported species. It was
geographically associated with the area of Aleppo, and causes anthro-
ponotic cutaneous leishmaniasis. L. infantum, localized in the coastal
border of Syria, is the causative agent of the relatively rare visceral
leishmaniasis. In Turkey and Lebanon, being neighbouring countries of
Syria, there have also been increased incidences of rare detected types
of leishmaniasis like L. major, which is often found in Damascus, and L.
donovani. As for the studies reviewed, L. tropica and L. major are the
most often mentioned Leishmaniasis species in the Syrian migrants
[12,14–17].
3.1.2. Colonisation with gram negative bacteria and other drug-resistant
microorganisms
Several studies have used rectal, nasal and pharyngeal swabs to
detect colonisation with microorganisms in Syrian refugees. Gram ne-
gative bacteria belonging to Pseudomonas sp., Aeromonas sp., Pantoea
sp., and Acinteobacter sp. were the most often detected microorganisms
[18]. The prevalence for multidrug-resistant Gram negative bacteria
(MDR GNB) was signiﬁcantly higher in the migrants than that in local
populations. Moreover, the prevalence of methicillin-resistant Staphy-
lococcus aureus (MRSA) in migrants exceeded the rate in local non-mi-
grant groups [18–22]. One study described two cases of NDM-1 pro-
ducing Acinetobacter baumanii ST85 in Turkey, one of these isolates was
from a Syrian refugee [23].
Another study indicated a higher prevalence of Trichomonas vagi-
nalis in Syrian migrants compared to local Turkish inhabitants [24]. A
further study described a Syrian migrant with Cornyebacterium diph-
teriae [25]. In addition, there was a report of an 11 years old Syrian
refugee girl living in Turkey diagnosed with meningococcal meningitis
type B [26]. There were two papers about brucellosis. Species identi-
ﬁcation of Brucella melitensis was shown in almost all cases, B. suis was
only detected in one case [27,28]. Many scabies infections were
observed [29]. In a cohort of Syrian unaccompanied minors (UAMs)
arriving in Germany the most frequent diagnosis was intestinal para-
sitosis. The majority were non-pathogenic parasites, 12.2% were diag-
nosed with Blastocystis spp. The pathogenic parasite most diagnosed
was Giardia duodenalis with 7.2% [30,31]. Among fungi, unusual spe-
cies such as Alternaria alternata and Pencillium were isolated [18].
3.1.3. Polio
Some studies detected enteroviruses in Syrian refugees, some of
these cases with the evidence of the poliovirus (PV). Intratypic diﬀer-
entation of PV revealed Sabin-like Poliovirus, indicating a recent oral
polio vaccination or contact to a OPV vaccinee; wild-type Poliovirus
was not detected [32–35]. A seroprevalence study showed high ser-
oprevalence against all three PV types, similar to the population living
in Germany [33].
3.1.4. Hepatitis
The studies show that the risk of hepatitis B and C in Syrians is very
low, most of the selected studies showed no or an insigniﬁcant number
of cases [18,31,36,37]. Only one study at the Syrian border to Turkey
detected a signiﬁcant diﬀerence between the hepatitis B incidence in
Syrian refugees compared to local Turkish inhabitants and this led to
the recommendation for hepatitis B screening of refugees entering
Turkey [38]. The risk of hepatitis C in Syria and the Middle East is also
very low except for at-risk groups such as drug users presenting high
incidences [37,39]. The most common hepatitis C genotype in Syria is
genotype 4 [39].
3.1.5. Tuberculosis
The prevalence of active tuberculosis is very low in Syrian asylum
seekers [40–43]. A study that analysed all migrants who arrived in
Germany identiﬁed a higher rate (76 cases per 100,000 screened) of
tuberculosis for asylum seekers compared to the general population in
Germany. However, diﬀerences between the countries of origin exist:
Prevalence was higher in Eritrean asylum seekers compared to Syrians.
Rates in all asylum seekers are higher than in the host German popu-
lation [40]. A study in Turkey showed a similar prevalence of tu-
berculosis in refugees from Syria compared to the Turkish population
[41].
Fig. 4. Numbers of papers identiﬁed in the systematic review by infection type in Syrian and Eritrean migrantsNote
: The size of the dot/diamond signiﬁes the relevance of a particular infection for a particular migrant group.
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3.2. Infectious disease papers addressing Eritrean migrants (results)
3.2.1. Louse borne relpasing fever (LBRF)
This systematic review identiﬁed several studies describing LBRF
amongst Eritrean migrants [44–51]. Attendent secondary diseases were
scabies and impetigo [51].
3.2.2. Malaria
Both Plasmodium vivax and Plasmodium falciparum cases were re-
ported in studies of Eritrean migrants. Most of the cases were P. vivax.
The studies could not identify the area of acquisition of malaria or
conﬁrm whether the malaria was acquired in Eritrea or along the mi-
gration route. Three cases of P. ovale in Eritrean migrants were detected
[7,8,43,52].
3.2.3. Tuberculosis
For asylum seekers from Eritrea, active tuberculosis is more fre-
quently reported than in Syrian migrants. Most of the cases reported in
Eritreans are pulmonary TB, only a few extrapulmonary cases were
detected [40,43,53–56].
3.2.4. Schistosomiasis
In some studies cases of Schistosomiasis were detected in migrants
from Eritrea [43,57–59]. Type speciﬁcation shows in every case where
it is described Schistosoma mansoni. One study proved the high sensi-
tivity of point-of-care circulating cathodic antigen (POC-CCA) test on
urine for S. mansoni. This test can improve the S. mansoni detection rate,
but the sensitivity for detection of S. haematobium is not suﬃciently
high [57,60]. This parasitic disease has a very unspeciﬁc clinically
presentation, can also present with neurologic symptoms [59].
3.2.5. Scabies and other microorganisms
Several papers described scabies in migrants from Eritrea, often in
combination with other infections. In one study, 14 methicillin-sus-
ceptible and one methicillin-resistant Staphylococcus aureus expressing
the Panton-Valentine leucocidin (PVL) are reported. In 14 of the 15
patients the clinical presentation was a skin infection. 6 cases (including
5 Eritrean migrants) presented scabies infestation and it was suggested
that scabies favoured secondary infection by PVL-encoding S. aureus
[61].
One study described 12 cases of Cornyebacterium diphtheriae-asso-
ciated wound infections in migrants from Eritrea. The microbiological
analyses showed that C. diphtheriae-associated wound infections most
often occurred together with further pathogens such as S. aureus and
Streptococcus pyogenes. In 3 cases there was a co-infection with scabies
[25]. Scabies also presented as co-infection of Louse-borne relapsing
fever [46,51]. Scratching of the lesions increased the risk of bacterial
infections [62].
One case of invasive meningocococcal disease W:P1.5,2:F1-1:ST-11
in an Eritrean migrant was also described [63].
4. Discussion
This systematic review describes the infection disease proﬁle of two
groups of migrants, Syrian and Eritrean, who travelled to Europe, as
reported in papers identiﬁed in this systematic review of the literature.
The strongly increased emigration from Syria, a country with an
above average rate of cutaneous leishmaniasis incidences amongst
Arabic countries, has resulted in increased incidences of this disease in
countries hosting the Syrian migrants [64]. Until 2013, leishmaniasis
was rarely observed in the neighbouring countries of Syria, such as
Lebanon and Turkey [15,65]. In Lebanon, the cases (found in this
systematic review) were reported mainly in Lebanese districts such as
the Bekaa district which is close to the Syrian border and had the
highest percentage of cases (70.3%) as well the highest incidence
among Syrian refugees (38 cases/100,000) [65]. In Turkey, more than
98% of the cases of CL, found in this study, are reported from the South
and Southeastern Anatolian regions, thus, also in areas close to Syria
[13].
Syria, itself, already a country with a signiﬁcant incidence of cuta-
neous leishmaniasis before 2011, has seen an increase of its rate due to
the civil war: on the one hand, within the population of the country
itself, and also, in neighbouring countries where Syrians have migrated
and often live in suboptimal conditions that favour further spread of
this sandﬂy-borne infection. As war brings general existential in-
securities and population displacement with concomitant poverty, poor
housing and malnutrition and thus weakened immunity, all of which
can increase the relative risk of cutaneous leishmaniasis. Concerning
the current overall situation in Syria and its neighbouring countries, the
increase of cutaneous leishmaniasis can be considered as the most es-
sential deterioration of health conditions due to the Syrian civil war.
The absence of an eﬀective vaccine or any preventative drug for
leishmania adds to the challenge of control and restricts containment
eﬀorts to limiting human exposure to the potential vectors and the
eradication of the sandﬂy [65].
Counteractive measures have been applied. Systematic coordination
of these activies is necessary in order to successfully identify the hot-
spots and the spread of the disease, both aspects requiring a speciﬁc
identiﬁcation of the type of Leishmaniasis [12].
The distribution of Leishmania spp. overlaps with sand ﬂy habitats
and disease reservoirs. Expanisve Phlebotomus papatasi and the Ph.
sergenti sand ﬂy populations exist in Syria and Iraq. Anthroponotic cu-
taneous leishmaniasis is caused by L. tropica and transmitted between
humans by the Ph. sergenti sand ﬂy. Zoonotic cutaneous leishmaniasis is
caused by the protozoan parasite L. major which is transmitted through
the infectious bite of the female Ph. papatasi and the Ph. duboscqi sand
ﬂy. Zoonotic visceral leishmaniasis is caused by L. infantum and trans-
mitted through diﬀerent species of sandﬂies. Ph. orientalis as well as Ph.
alexandi are known as vectors of L. donovani which causes anthro-
ponotic visceral leishmaniasis [15,16,64]. As far as the Arab countries
are concerned, Syria is the country representing most cases of cuta-
neous leishmaniasis whereas Iraq reports most cases of visceral leish-
maniasis [64].
In 2013 and early 2014, there was a polio outbreak in Syria with
more than 30 cases. The last outbreak before was detected in 1999. In
the period preceding the recent outbreak, the oral polio vaccine cov-
erage had fallen to 52% among infants between the ages of 12–23
months nationwide. Due to mass vaccination campaigns, Syria is now
approaching two years without a reported case of polio. Screening in
Germany and Bugaria only showed sabin-like poliovirus, no wild-type
poliovirus was detected [32–35,66,67].
Considering the infectious disease proﬁle of Eritrean migrants,
Louse-borne relapsing fever (LBRF) caused by Borrelia recurrentis is
strongly represented. This infection was once a major disease burden
that caused major epidemics in Africa and Eurasia in the past. In the
early 20th century, there were several, massive outbreaks in Eastern
Europe, for example in Serbia during World War I and in Russia during
the civil war. Now the infection has been restricted to East Africa for
many decades with most cases reported in Ethiopia [44,48,68–70]. In
2015, around 30 cases of LBRF were diagnosed in Europe, most of these
cases concerned migrants from Somalia, a few from Eritrea as well as
from Ethiopia. It is diﬃcult to determine whether the Eritrean migrants
contracted the disease in their home country or on their way to Europe.
Given the long duration of travel ranging from eight weeks to one year,
on the one hand, and the short incubation time of 2–15 days, on the
other hand, infection with Borrelia recurrentis was most likely acquired
along the migration routes towards the end of their journeys, in Libya
or Italy. The exact place of infection remains unclear. Somehow the
country of origin nevertheless seems to matter as no migrants from
other African regions are infected by LBRF although they increasingly
share their migration routes closer they get to Europe [44,45,50,51].
This louse-borne relapsing fever is transmitted from human to human
E. Isenring et al. Travel Medicine and Infectious Disease xxx (xxxx) xxx–xxx
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Table 2
Infections in Eritrean migrants.
Almog et al.
2016 B. pseudomallei
Case report Burkholderia pseudomallei isloated in a 45y-old Eritrean migrant worker in Israel.
Meier et al. [40]
2016 TB
Prospectivedescriptive epidemiology
study
11,773 newly arived asylum seekers in Germany were investigated, about 1% came from
Eritrea. 11 Conﬁrmed cases of tuberculosis: 93/100′000; 5 Eritrean patients had active
tuberculosis (ca 45% of detected active TB cases).
Roggelin et al. [7]
2016 Malaria
retrospective study 37 cases of Plasmodium vivax malaria between 2014–August 2015 in Eritrean refugees.
There was no concomitant increase in P. falciparum cases. Therefore, a relative increase of
P. vivax malaria from only 2% of all cases in 2103 to 26% in 2014 and 34% in 2015. 92%
of cases were male, median age was 19 years, 35% were of minor age (< 18); One patient
had a mixed infection with P. falciparum.
Jaton et al. [61]
2016 S. aureus, Scabies
case series 11/15 Staphylococcus aureus strains belonged to only two clonal complex (CC152 and
CC15). The largest cluster of 8 CC152 cases of skin infections aﬀected mainly Eritrean (4)
refugees, 2/4 with scabies. 3 patients infected by CC15 strains, all Eritreans, 1 with scabies
as co-pathogen infection. 5/11 CC152/CC15 cases presented scabies infestation (all
Eritrean migrants).
Müller et al.
2016
retrospective single-center analysis Patients orginated in Eastern Africa (27.7%) or Western Asia (22.6%). The most common
countries of origin were Eritrea (13%), Somalia (13%) and Syria (11%). Ca 50% patients
were treated for infections (16.8%)
Osthoﬀ et al. [44]
2016 LBRF
case series 4 cases of Louse-borne relapsing fever in Switzerland: 1 from Eritrea (25 year old male):
Travel route from Eritrea-Sudan-Libya-Italy-CH; No additional diagnosis, no Jarisch-
Herxheimer reaction; First febrile epsode in Libya.
Stefanelli et al. [63]
2016 Meningitis
case series 3 cases of invasive meningocococcal disease, 1 in a 20y old woman from Eritrea. DNA
extraction from cerebrospinal ﬂuid: molecular identiﬁcation of Neisseria meningitides
serogroup W. Multilocus sequence Typing, PorA and FetA typing: W:P1.5,2:F1-1:ST-11
clonal complex (cc) strain in all samples.
Hoch et al. [45]
2015 LBRF
case series 15 cases (males, median age: 20 years) of Louse-borne relapsing fever from the Horn of
Africa, 2 from Eritrea. LBRF most likely not acquired in their countries of origin but on
migration routes, possibly Libya or Italy
Wilting et al. [46]
2015 LBRF, Scabies
case series 2 cases (young adults) of Louse-borne relapsing fever from Eritrea. About 80% of all new
arrivals from Eritrea present clinically manifest scabies.
Becker et al. [57]
2015 Schistosomiasis
case series 2 cases of Schistosoma mansoni in Eritrean migrants. Use of point-of-care (POC) circulating
cathodic antigen (CCA) test on urine comﬁrmed S. mansoni infection in both patients.
Sondén et al. [8]
2014 Malaria
case series 105 cases of malaria from Eritrea (84 infected with Plasmodium vivax, 5 with P. falciparum,
3 with P. ovale; 13 with unspeciﬁed species). The estimated P. vivax incidence rate 2014:
19.5/1000 Eritrean asylum seekers and 38.2/1000 Eritrean seekers< 18y. High
transmission of P. vivax along the route of migration: Travel route through Ethiopia and/
or Sudan.
Padovese et al. [53]
2014 TB, Hep B/C, STID, HIV
case series 500 migrants in Maltese open centers: 8.2% from Eritrea. Out of the 49.6% Tuberculin
skin test (TST)-positive migrants, 86% underwent a chest x-ray, 14.9% (32) lung
abnormalities, 60% of them resulted positive to IGRA.
STI screening: low prevalence of HBsAg (6.2%), latent syphillis (2.2%), and HCV
antibodies (0.6%); negative results for HIV.
Grande et al. [52]
2015 Malaria
case series 2013–2014: Large increase in P. vivax malaria attributed to increased numbers of Eritrean
migrants.
Uccella et al. [54]
2015 TB
A retrospective single center study 51,287 migrants presenting in Rome. 22 Tuberculosis cases were notiﬁed (0.4/1000).
59.1% of cases had origin in Africa → 13.6% Eritrea. Active TBC prevalence among
foreigners resulted low.
Mor et al. [55]
2015 TB
A cross-sectional study 5335 undocumented migrants from the Horn of Africa, 20.4% (1087; 59% from Eritrea)
underwent Chest X-ray (CXR), 5.7% (62) of the (CXRs) had radiological ﬁndings
suggestive of Tuberculosis (TB); 17.7% (11) of all suspicious CXRs diagnosed as having TB
(45.4% (5) of the cases with TB are from Eritrea); 90.9% pulmonary TB, 9.1%
extrapulmonary TB; Sputum-smear positive results in 27.3%, and positive culture in
72.7%; 3years follow-up: 88 migrants from the Horn of Africa were diagnosed with TB in
the community after being discharged from detention where they had TB screening:
62.5% (55) Eritreans, 59 (67%) were diagnosed with pulmonary TB. CXR-based screening
is a valid and cost saving tool for TB screening.
Mammina et al. [56]
2014 TB
Observational study 2010–2013: 876 Tuberculosis cases were notiﬁed in Sicily with a mean annual notiﬁcation
rate of 4.44 cases per 100′000 inhabitants; The proportion of TB cases in foreign-born
individuals was increasing and higher than the proportion in Italian-born. The median age
of foreign-born patients was signiﬁcantly lower than the Italian born (30.5 vs. 51.2 years).
82% of cases were pulmonary. Molecular typing of 151 Mycobacterium tuberculosis
complex (MTBC) isolates identiﬁed in Palermo in 2012 and 2013 detected 14 lineages and
33 sublineages showing a diﬀerent distribution among the two patients sub-populations:
Wide heterogenity of MTBC isolates. Only nine MTBC isolates (6.2%) grouped in four
clusters. Two multidrug resistant (MDR) MTBC isolates identiﬁed from an Italian born
elderly patient and an Eritrean young patient (Beijing lineage).
Kesztyüs et al. [47]
2016 LBRF
case-series 2 young male refugees with Louse-borne Relapsing Fever from Eritrea.
(continued on next page)
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via the human body louse Pediculus humanus humanus. This insect
prefers conditions of overcrowding and poor hygienic conditions, often
observed on migration routes and in camps and thus easily explaining
its recovery from the clothing in some patients. Cold weather and hu-
midity are other important factors for the prevalence of the human
body lice and so during the winter months louse-transmitted diseases
are more frequently reported [44,46,48,69,70]. Our review shows that
mortality is estimated at between 30% and 70% for untreated cases and
2%–6% for those receiving appropriate treatment [44,45]. Con-
comittant disease like malaria is common [71]. As far as the therapy of
LBRF infection is concerned, this is usually performed with the anti-
biotic ceftriaxone and/or doxycycline. It is important to be aware of the
possible Jarisch-Herxheimer reaction: this immune reaction, including
the symptoms of aggravated hypotension, tachycardia, high-grade fever
and deteriorated condition, is often a result of this antibiotic therapy
and should be carefully monitored [46].
An increased infection rate of scabies is another result of the poor
conditions the migrants from Eritrea and Syria are confronted with
during their long and strenuous migration. On their way to Europe, a lot
of asylum seekers stayed in several diﬀerent camps and were often
forced to sleep in places with poor hygiene thus signiﬁcantly increasing
their exposure to scabies [29] [72]. As was found in our review, 80% of
the Eritrean arrivals are infected by scabies. This is why, simultaneously
to the delousing because of the LBRF, arrivals are often treated with a
Table 2 (continued)
Kreuzberg et al. [58]
2015 Schistosomiasis, Giardia duodenalis,
Hepatitis B
A retrospective study Between September 2014 and April 2015, 160 minor refugees (15-17y old) were screened.
In 21/140 assessed blood samples, eosinophila of more than 450/μl was found, strongly
associated with sub-Saharan Africa origin (P= 0.007). 27% (10/37) of the refugees
showed blood eosinophilia and 57% (8/14), respectively, came from Eritrea
(P= 0.00004). Stool microscopy (114 samples) detected Schistosoma mansoni (n=3),
Giardia duodenalis (n= 2) and Hymenolepis nana (n= 1). Multiplex stool PCR (98
samples) tested nine more cases positive for Schistosoma (total n= 12 (7.5%)).
Schistosomiasis was associated with eosinophilia, origin from sub-Saharan Africa,
especially Eritrea. PCR also detected 10 further infections with Giardia duodenalis (7.5%,
12/160). No regional preferences Anti-HBc was positive in 11.3% (18/160) of cases, three
of them developed chronic hepatitis B. Anti-HBc positivity was signiﬁcantly higher in
refugees from Sub Sahara Africa (P < 0.001). Eosinophilia, helminth and most protozoan
infections – with the exception of giardiasis – are more frequent in refugees coming from
sub-Saharan Africa than from other regions.
Alberer et al. [43]
2015 Scabies, Malaria, Schistosomiasis, TB
retrospective study In Munich 219 migrants were screened yielding 53 cases of tuberculosis → 43 pulmonal;
16 of which were from Eritrea. 10 extrapulmonary, 3 from Eritrea (1 multiresistent). 53
cases of malaria: 46 Plasmodium vivax, 43 from Eritrea; 7 P. falciparum, 5 from Eritrea. 15
cases of schistomiasis, 11 from Eritrea; Many scabies cases.
Goldenberger et al. [48] 2015 LBRF case report Report of an imported case of Louse-Borne Relapsing Fever in a young adult Eritrean
refugee who presented with fever shortly after arriving in Switzerland.
Antinori et al. [49]
2016 LBRF
systematic review Up to November 2015, at least 28 cases of louse-borne relapsing fever have been
diagnosed among East African refugees, all patients were male, young and all cases but 2
had recently arrived in Europe. 21 from Somalia, 5 from Eritrea, 1 from Ethiopia. In most
of the cases, Libya was the last country in Africa where they had resided before arriving in
Europe. Onset of symptoms was reported before the arrival in Europe in 10 out of 19
patients. Body lice infestation in 5 out of 17 patients.
Colomba et al. [50]
2016 LBRF
Mini review and case report 26 cases of louse-borne relapsing fever between July and October 2015 in migrants
recently arrived in Europe: 8 in Italy (3 in Sicily, 5 in Piedmont), 1 in Switzerland, 2 in the
Netherlands, 15 in Germany (Bavaria). 21 cases from Somalia, 5 cases from Eritrean, one
case from Ethiopia. In most Eritrean cases, infestation with lice was present. All the cases
had similar clinical presentation chracterized by malaise, fever, headache, myalgia, ﬁve
had vomitting and three abdominal pain, one patient was afebrile. The outcome was good
in all but one case died of multi-organ failure after initation of AB Therapy despite
intensive care treatment. Jarisch-Herxheimer reaction in 15 (58%) of the patients.
Haas et al.
2014 Varicella
Outbreak description 2500 detainees from Eritrean and Sudan in southern Israel in two facilities. 109 cases of
primary varicella had been reported over a 7-month period: infection rate: 4.4%. The
outbreak described in this study stopped within one incubation period after vaccine
initation despite an overall 15.6% vaccine refusal rate
Lesens et al.
2016 Varicella
Outbreak description 31 migrants. 29 were Sudanese males, two were an Eitrean husband and his pregnant
wife. A total of 12 persons in this group had contracted varicella since they had arrived in
France (Attack rate: 39%). All except one had a positive varicella serology (96%). All the
men in the group were already immune, except for the man of Eritrean origin whose wife
was pregnant (her serology was positive). In contrast to these results, all except one (the
pregnat Eritrean woman) were immunized against measles. Varicella outbreaks may occur
in refugees from East Africa who are scantly immunized against VZV
Gautschi et al. [59]
2015 Schistosomiasis
case report Schistomiasis diagnosed by Serum ELISA in a 34 year-old man from Eritrea presented with
gradual onset bilateral loin and leg pain; Schistosoma mansoni conﬁrmed by a stool sample.
Meinel et al. [25]
2016 Corn. diptheriae
S. aureus, Scabies
20 refugees with Cornyebacterium diphtheriae-associated wound infections presented in
Switzerland and Germany, 12 refugees from Eritrea. C. diphtheriae-associated wound
infections most often occurred in combination with Staphylococcus aureus and
Streptococcus pyogenes. 4 cases methicillin-resistant S. aureus (1 Eritrean refugee). 9 cases
methicillin-sensitive S. aureus (7 in Eritrean refugees). 15 cases S. pyogenes (11 in Eritrean
refugees). 3 cases Scabies (3 in Eritrean refugees).
Seilmaier et al. [51]
2016
LBRF, Scabies
case series August 2015 – Januar 2016: 25 patients presented in the clinic in Munich with louse-
borne relapsing fever, 23 from Somalia, 2 from Eritrea. 24/25: Travel route via Sudan and
Lybia over the Mediterranean sea to Italy und ﬁnally to Germany. One case from Somalia
via Jemen and then via Sudan and Lybia to Europe. 6/25 Scabies; Case 1 from Eritrea:
secondary diseases: Scabies und Impetigo, Case 2 from Eritrea: No secondary disease. Both
patients from Eritrea: No detection of the bodylouse in the clothes, no signs on the skin. In
both cases the Jarisch-Herxheimer-Reaktion was described.
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single dose of ivermectin as pre-emptive treatment. Those with clini-
cally manifested scabies receive a second dose a week later [46].
As far as malaria is concerned, Eritrean migrants when arrived in
Europe are mostly diagnosed with P. vivax malaria although P. falci-
parum is the dominant species in their country of origin. Migrants may
have received schizontocidal anti-malarials (that elimate P. falciparum
and the blood stages of P. vivax) prior to, or during travel. This may be
the reason why late-onset P. vivax occurred in Europe. Alternatively the
migrants may have acquired their P. vivax malaria along the migration
route. Geographical hotspots of P. vivax transmission are likely to be
situated along the route of migration [7,8,73]. Three cases of P. ovale
were described in Eritrean migrants. They may have acquired P. ovale in
camps in Northern Africa where many migrants from West Africa are
accommodated [7].
It was found in this systematic review that the risk of active tu-
berculosis is low when it comes to Syrian migrants. The prevalence of
TB was very low in Syria, even during the civil war (19/100′000 in
2014) and signiﬁcantly higher for Syrian migrants as the TB transmis-
sion is fostered within refugees communities on their common journey
to Europe [40,41,43,66]. Concerning the migrants from Eritrea more
cases with active tuberculosis were detected [43,54–56]. In one study, a
co-incidence of TB with HIV is described. There was one single positive
case of HIV in a group of 11 TB positive persons. It was conﬁrmed that
this individual with HIV/TB co-infection originated in Ethopia not
Eritrea (personal communication Mor) [55].
A special consideration should be given to multidrug resistance
(MDR) tuberculosis. Military conﬂicts and the resulting population
conﬂit increase the risk of MDR, also because unﬁnished or rather in-
terrupted drug therapies often happen on the migrant's way to their
destination country. Early detection is of great importance in order to
prevent resistant tuberculosis as the experience with migrants from
Eastern Europe or other countries with high risk of MDR has clearly
shown in the past [74,75].
For TB, the screening strategy is highly important if countries want
to guarantee an eﬀective as well as eﬃcient identiﬁcation: as a ﬁrst
step, the tuberculin skin test is used for latent TB infection screening,
but has many limitations including high rates of cross-reactivity with
BCG vaccination and so the speciﬁty is very low [53]. Chest x-ray (CXR)
has a high sensitivity and is a valid and cost-saving approach, but the
speciﬁty is low as well [55]. The high sensitivity allows for shorter
delays between screening and the start of treatment [76]. However,
CXR can miss migrants with latent TB infections that may reactivate at
a later stage. Furthermore, CXR is not an appropriate tool for detecting
cases of extra-pulmonary TB. Finally, the strategy of symptom-based
interview is useful when it comes to identify target groups with speciﬁc
risks in general but has signiﬁcant limitations as a screening tool.
The risk of HIV in asylum seekers from Syria is low and can be
explained by their religious rules imposing restrictive behaviour re-
garding sexual habits. The same applies to the risk of sexual transmitted
diseases in Eritrean migrants [53]. From a total of 443 Eritrean mi-
grants tested on arrival in Malta, none were positive for HIV and none
had STI symptoms. With regard to hepatitis, 32 were positive for he-
patitis B and none were positive for hepatitis C (personal communica-
tion Padovese).
This systematic review allows for the following ﬁnal considerations:
Because of the breakdown in the Syrian health care system, the vacci-
nation coverage has dropped [66] and outbreaks of vaccine-preventable
diseases such as polio and measles have been observed in Syria itself
[77]. With regard to the migrants from Syria, it is important to note that
no wild type polio has been reported. The results of this systematic
review and background literature suggest that vaccination records of
the migrants should be checked and if unavailable or incomplete, then
vaccination should be done in accordance with age of the migrant and
the vaccination schedule of the host countries and the living conditions
in the refugee/migrant camp. Vaccinations to be considered should
include measles-mumps-rubella, varicella, Haemophilus inﬂuenza B and
a booster dose of tetanus-diphtheria-polio-pertussis [72,78]. Inﬂuenza
can also be considered in view of the crowded living conditions and as
additional protection against both inﬂuenza and norovirus infection,
supplies of hand sanitizers should be recommended. The risk of tu-
berculosis in the Middle East region remains low but in a refugee camp
the rates of transmission can be increased and interrupted or in-
adequate treatment may increase the risk of MDR TB. There is no
consensus in host countries with regard to TB screening and treatment
and this is an area for urgent action. Currently work is under way to
identify migrant vaccination practices in Europe with the goal of es-
tablishing a uniﬁed approach. One study has shown a seroprevalence of
only 50% in Syrian children aged less than 10 years so hepatitis A may
be a risk for this age group and age selective vaccination may be ap-
propriate [79]. Screening for chronic hepatitis B virus infection and
prior immunity as well as the vaccination can also be recommended for
those who are susceptible. Our analysis shows a low prevalence of
hepatitis C in Syrian migrants, except for risk groups, suggesting that
hepatitis C screening is not a priority. Similarly the reports for both
Eritreans and Syrians suggest a low HIV prevalence [39,53].
Furthermore, this systematic review clearly shows that for Eritrean
migrants presenting with fever the most likely diﬀerential diagnoses are
malaria and louse-borne relapsing fever. As the malaria type mostly
detected amongst Eritrean migrants is P.vivax, adjunct therapy with
primaquine required and the logistics of have primaquine available can
be daunting as primaquine is diﬃcult to procure in many countries.
LBRF, diagnosed by spirochetes identiﬁed in stained blood ﬁlms and
conﬁrmed by PCR that targets the 16SrRNA gene. LBRF must be treated
with antibiotics (mainly doxycycline) [44,50]. As far as this therapy is
concerned, checking for Jarisch-Herxheimer-reaction is a must.
Due to the speciﬁc circumstances of their journey with crowded
conditions for a prolonged period, many migrants will present with
scabies which is why a presumptive treatment of all arrivals is the most
eﬀective and eﬃcient way to deal with this infection [46].
With regard to Syrian migrants, colonisation with resistant micro-
organisms is an area of concern.
As there is no vaccine or preventive therapy against leishmania, this
infection easily spreads amongst refugees and it is necessary to con-
stantly check for this disease using microscopic examination of skin
lesions. Apart from the standard therapy with pentavalent antimonials
it is recommended to focus on vector control and to eliminate sand-ﬂy
contamination in the geographic locations of the refugee camps thus
steming the actual cause of the disease.
5. Conclusions
This systematic review concludes that leismaniasis and the coloni-
sation with antibiotic resistant gram negative bacteria present the most
relevant infectious disease challenges in Syrian migrants.
With regard to the Eritrean migrants, Louse-Borne Relapsing Fever,
scabies, Plasmodium vivax malaria and schistosomiasis were the most
frequently reported infections.
These data will be of public health value in creating evidence-based
screening protocols and will enable host countries to adequately pre-
pare to the infectious disease conditions in migrant populations.
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Appendix
Electronic database searching for Eritrea (last search on March 31,
2017). Filter for publication date from 01.01.2014 to 31.12.2016.
a) Pubmed: “eritrea*“, “infect*“ and migra* retrieved 16 hits, “eri-
trea*“, “infect*“ and refugee* retrieved 11 hits
b) EMBASE: “eritrea*“, “infect*“ and migra* searched in all ﬁelds re-
trieved 22 hits, “eritrea*“, “infect*“ and refugee* retrieved 20 hits
c) Scopus: “eritrea*“, “infect*“ and migra* in all ﬁelds retrieved 113
hits, “eritrea*“, “infect*“ and refugee* retrieved 82 hits
d) CINAHL: “eritrea*“, “infect*“ and migra* retrieved 0 hits, “eri-
trea*“, “infect*“ and refugee* retrieved 1 hit
Electronic database searching for Syria (last search on March 31,
2017). Filter for publication date from 01.01.2014 to 31.12.2016.
a) Pubmed: “syria*“, “infect*“ and migra* retrieved 12 hits, “syria*“,
“infect*“ and refugee* retrieved 35 hits,
b) EMBASE: “syria*“, “infect*“ and migra* searched in all ﬁelds re-
trieved 41 hits, “syria*“, “infect*“ and refugee* retrieved 76 hits
c) Scopus: “syria*“, “infect*“ and migra* in all ﬁelds retrieved 441
hits, “syria*“, “infect*“ and refugee* retrieved 215 hits
d) CINAHL: “syria*“, “infect*“ and migra* retrieved 1 hits, “syria*“,
“infect*“ and refugee* retrieved 4 hits.
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